Market Overview

J&J's Janssen Announces Intent Not to Enforce Patents for Darunavir

Related JNJ
AbbVie Candidate in Pivotal Study - Analyst Blog
Dow 30 Stock Roundup: JNJ Beats, JPM Disappoints - Analyst Blog
Stock Futures Tick Up Amid Upbeat Earnings (Fox Business)

J&J's (NYSE: JNJ)  Janssen Pharmaceutical Companies today announced their intention not to enforce the patents they own and control on the antiretroviral (ARV) drug darunavir provided the darunavir product is medically acceptable and is used only in resource-limited settings.^1 This announcement is intended to assure generic manufacturers that they may manufacture high quality darunavir product used in SSA and the LDCs without a concern that Janssen will accuse these activities of infringing its darunavir patents.

This new policy anticipates a greater future need to supply affordable generic versions of darunavir (brand name PREZISTA^®) for the treatment of people living with HIV in the territory, and is consistent with the Company's focus on access to medicines in those countries with the highest rates of HIV infection and economic vulnerability.

Posted-In: News

 

Most Popular

Related Articles (JNJ)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free